Rare Kidney Diseases Market

Rare Kidney Diseases Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Fabry Disease, Immunoglobulin A Nephropathy, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney Disease, Lupus Nephritis and Others), Type of Molecule (Small Molecules and Biologics), Type of Biologics (Monoclonal Antibodies and Proteins), Route of Administration (Oral, Intravenous, Subcutaneous, and Others), Type of Therapy (Monotherapy, Combination Therapy), Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World), Leading Drug Developers and Sales Forecast

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    190

  • Slides
    240

  • View Count
    10271

Table Of Contents

1. RESEARCH METHODOLOGY

2. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3. EXECUTIVE SUMMARY
 
4. INTRODUCTION
4.1. Overview of Kidney Diseases
4.1.1. Key Historical Events related to Kidney Diseases
4.1.2. Factors Contributing to Kidney Diseases

4.2. Overview of Rare Kidney Diseases
4.2.1. Types of Rare Kidney Diseases
4.2.2. Challenges Associated with RKD Diagnosis and Treatment

4.3. Selection of Therapeutic targets for Rare Kidney Diseases
4.4. Technological Advancements in the Rare Kidney Diseases Domain
4.5. Recent Developments in the Rare Kidney Diseases Domain
4.6. Future Perspectives
 
5. MARKET LANDSCAPE
5.1. Rare Kidney Disease Therapies: Market Landscape
5.1.1. Analysis by Phase of Development
5.1.2. Analysis by Route of Administration
5.1.3. Analysis by Type Molecule
5.1.4. Analysis by Target Disease Indication
5.1.5. Analysis by Type of Biologic
5.1.6. Analysis by Type of Therapy
5.1.7. Analysis by Dosing Frequency
5.1.8. Analysis by Target Patient Segment
5.1.9. Key Facts on Drug Designation
 
6. RARE KIDNEY DISEASE THERAPIES: DETAILED COMPANY PROFILES
6.1. Chapter Overview
6.1.1. Alexion Pharmaceuticals
6.1.1.1 Company Overview
6.1.1.2 Financial Information
6.1.1.3 Pipeline Portfolio
6.1.1.4 Recent Developments and Future Outlook

6.1.2. Chinook Therapeutics
6.1.2.1 Company Overview
6.1.2.2 Financial Information
6.1.2.3 Pipeline Portfolio
6.1.2.4 Recent Developments and Future Outlook

6.1.3. Horizon Therapeutics
6.1.3.1 Company Overview
6.1.3.2 Financial Information
6.1.3.3 Pipeline Portfolio
6.1.3.4 Recent Developments and Future Outlook

6.1.4. Jiangsu Hengrui Pharmaceuticals
6.1.4.1 Company Overview
6.1.4.2 Financial Information
6.1.4.3 Pipeline Portfolio
6.1.4.4 Recent Developments and Future Outlook

6.1.5. Novartis
6.1.5.1 Company Overview
6.1.5.2 Financial Information
6.1.5.3 Pipeline Portfolio
6.1.5.4 Recent Developments and Future Outlook

6.1.6. Omeros
6.1.6.1 Company Overview
6.1.6.2 Financial Information
6.1.6.3 Pipeline Portfolio
6.1.6.4 Recent Developments and Future Outlook

6.1.7. Roche
6.1.7.1 Company Overview
6.1.7.2 Financial Information
6.1.7.3 Pipeline Portfolio
6.1.7.4 Recent Developments and Future Outlook

6.1.8. Sanofi
6.1.8.1 Company Overview
6.1.8.2 Financial Information
6.1.8.3 Pipeline Portfolio
6.1.8.4 Recent Developments and Future Outlook

6.1.9. Travere Therapeutics
6.1.9.1 Company Overview
6.1.9.2 Financial Information
6.1.9.3 Pipeline Portfolio
6.1.9.4 Recent Developments and Future Outlook

6.1.10. ZyVersa Therapeutics
6.1.10.1 Company Overview
6.1.10.2 Financial Information
6.1.10.3 Pipeline Portfolio
6.1.10.4 Recent Developments and Future Outlook
 
7. RARE KIDNEY DISEASE THERAPIES: SHORT COMPANY PROFILES
7.1. Chapter Overview
7.1.1 Advicenne
7.1.1.1 Company Overview
7.1.1.2. Pipeline Portfolio

7.1.2. Apellis Pharmaceuticals
7.1.2.1 Company Overview
7.1.2.2. Pipeline Portfolio

7.1.3. argenx
7.1.3.1 Company Overview
7.1.3.2. Pipeline Portfolio

7.1.4. Astellas Pharma
7.1.4.1 Company Overview
7.1.4.2. Pipeline Portfolio

7.1.5. Boehringer Ingelheim
7.1.5.1 Company Overview
7.1.5.2. Pipeline Portfolio

7.1.6. Calliditas Therapeutics
7.1.6.1 Company Overview
7.1.6.2. Pipeline Portfolio

7.1.7. GSK
7.1.7.1 Company Overview
7.1.7.2. Pipeline Portfolio

7.1.8. Mallinckrodt Pharmaceuticals
7.1.8.1 Company Overview
7.1.8.2. Pipeline Portfolio

7.1.9. Synlogic
7.1.9.1 Company Overview
7.1.9.2. Pipeline Portfolio

7.1.10. Takeda
7.1.10.1 Company Overview
7.1.10.2. Pipeline Portfolio
 
8. COMPANY COMPETITIVENESS ANALYSIS
8.1 Key Parameters and Scoring Criteria
8.2. Analysis Methodology
8.3. Rare Kidney Disease Therapies Developers: Company Competitiveness Analysis
8.3.1. Rare Kidney Disease Therapies Developers based in North America (Peer Group I)
8.3.2. Rare Kidney Disease Therapies Developers based in Europe (Peer Group II)
8.3.3. Rare Kidney Disease Therapies Developers based in Asia-Pacific and Rest of the World (Peer Group III)

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Rare Kidney Disease Therapies: Partnerships and Collaborations
9.3.1 Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Target Disease Indication
9.3.5. Analysis by Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships

9.3.7. Analysis by Geography
9.3.7.1. Local and International Deals
9.3.7.2. Intercontinental and Intracontinental Deals
 
10. FUNDING AND INVESTMENTS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Rare Kidney Disease Therapies: Funding and Investments
10.3.1. Analysis by Year of Investment
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Analysis of Amount Invested by Type of Funding
10.3.5. Analysis of Amount Invested by Year and Type of Funding
10.3.6. Analysis by Target Disease Indication
10.3.7. Analysis by Geography
10.3.8. Most Active Players: Analysis by Number of Instances
10.3.9. Most Active Players: Analysis by Amount Invested
10.3.10. Leading Investors: Analysis by Number of Instances

11. CLINICAL TRIAL ANALYSIS
11.1. Analysis Methodology and Key Parameters
11.2. Rare Kidney Disease Therapies: Clinical Trial Analysis
11.2.1. Analysis by Trial Registration Year
11.2.2. Analysis by Trial Status
11.2.3. Analysis by Trial Registration Year and Trial Status
11.2.4. Analysis by Trial Registration Year and Patients Enrolled
11.2.5. Analysis by Trial Status and Patients Enrolled
11.2.6. Analysis by Trial Phase
11.2.7. Analysis by Study Design
11.2.8. Analysis by Trial Status, Trial Phase and Geography
11.2.9. Analysis by Type of Sponsor
11.2.10. Analysis by Gender of Patients
11.2.11. Most Active Industry Players: Analysis by Number of Trials
11.2.12. Most Active Non-Industry Players: Analysis by Number of Trials
11.2.13. Analysis by Geography

12. CLINICAL COMMERCIAL ATTRACTIVENESS
12.1. Methodology and Parameters
12.2. Key Parameters and Scoring
12.3. Clinical and Commercial Attractiveness Analysis: Phase III Drugs Targeting Rare Kidney Diseases

13. KEY OPINION LEADERS
13.1. Methodology and Key Parameters
13.2. Rare Kidney Disease Therapies: Key Opinion Leaders (KOLs)
13.2.1. Analysis by Type of KOL
13.2.2. Analysis by Type of Organization
13.2.3. Analysis by Target Disease Indication
13.2.4. Analysis by Industry Affiliated Organization
13.2.5. Analysis by Non-Industry Affiliated Organization
13.2.6. Analysis by Geographical Location of KOLs
13.2.7. Most Prominent KOLs: Peer Group 1 (Principal Investigators)
13.2.8. Most Prominent KOLs: Peer Group 2 (Study Directors)
13.2.9. Most Prominent KOLs: Peer Group 3 (Study Chairs)
13.2.10. Most Prominent KOLs: Analysis by RA Score

14. CASE STUDY
14.1. Scope and Key Parameters
14.2. Rare Kidney Disorders: List of Kidney Care Providers
14.3. Rare Kidney Disorders: Advantages of Kidney Care
14.4. Rare Kidney Disorders: Recent Developments

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion

16. RARE KIDNEY DISEASE MARKET
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Assumptions for Phase III Rare Kidney Disease Drugs
16.4. Forecast Model

16.5. Global Rare Kidney Disease Market, Historical Trends and Forecasted Estimates, till 2035
16.5.1. Scenario Analysis

17. RARE KIDNEY DISEASE MARKET, BY TARGET DISEASE INDICATION
17.1. Chapter Overview
17.2. Rare Kidney Disease Market: Distribution by Target Disease Indication, 2024, 2030 and 2035
17.2.1. Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome, till 2035
17.2.2. Rare Kidney Disease Market for Fabry Disease, till 2035
17.2.3. Rare Kidney Disease Market for Immunoglobulin A Nephropathy, till 2035
17.2.4. Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis, till 2035
17.2.5. Rare Kidney Disease Market for Autosomal Dominant Polycystic Kidney Disease, till 2035
17.2.6. Rare Kidney Disease Market for Lupus Nephritis, till 2035
17.2.7. Rare Kidney Disease Market for Others, till 2035
 
18. RARE KIDNEY DISEASE MARKET, BY TYPE OF MOLECULE
18.1. Chapter Overview
18.2. Rare Kidney Disease Market: Distribution by Type of Molecule, 2024, 2030 and 2035
18.2.1. Rare Kidney Disease Market for Small Molecules, till 2035
18.2.2. Rare Kidney Disease Market for Biologics, till 2035
 
19. RARE KIDNEY DISEASE MARKET, BY TYPE OF BIOLOGICS
19.1. Chapter Overview
19.2. Rare Kidney Disease Market: Distribution by Type of Biologic, 2024, 2030 and 2035
19.2.1. Rare Kidney Disease Market for Monoclonal Antibodies, till 2035
19.2.2. Rare Kidney Disease Market for Proteins, till 2035
 
20. RARE KIDNEY DISEASE MARKET, BY ROUTE OF ADMINISTRATION
20.1. Chapter Overview
20.2. Rare Kidney Disease Market: Distribution by Route of Administration, 2024, 2030 and 2035
20.2.1. Rare Kidney Disease Market for Oral, till 2035
20.2.2. Rare Kidney Disease Market for Intravenous, till 2035
20.2.3. Rare Kidney Disease Market for Subcutaneous, till 2035
20.2.4. Rare Kidney Disease Market for Others, till 2035
 
21. RARE KIDNEY DISEASE MARKET, BY TYPE OF THERAPY
21.1. Chapter Overview
21.2. Rare Kidney Disease Market: Distribution by Type of Therapy, 2024, 2030 and 2035
21.2.1. Rare Kidney Disease Market for Monotherapy, till 2035
21.2.2. Rare Kidney Disease Market for Combination Therapy, till 2035
 
22. RARE KIDNEY DISEASE MARKET, BY GEOGRAPHY
22.1. Chapter Overview
22.2. Rare Kidney Disease Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035
22.2.1. North America: Forecasted Estimates, till 2035
22.2.2. Europe: Forecasted Estimates, till 2035
22.2.3. Asia-Pacific: Forecasted Estimates, till 2035
22.3.4. Rest of the World: Forecasted Estimates, till 2035
 
23. RARE KIDNEY DISEASES MARKET, SALES FORECAST OF DRUGS
23.1. Chapter Overview
23.2. Approved Rare Kidney Disease Therapies Market: Sales Forecast
23.2.1. Agalsidase Beta BS I.V. Infusion / Agalsidase beta / JR-051 Sales Forecast
23.2.2. Benlysta® / Belimumab Sales Forecast
23.2.3. Elfabrio® / PRX-102 / Pegunigalsidase Alfa Sales Forecast
23.2.4. FILSPARI® / Sparsentan / RE-021 Sales Forecast
23.2.5. Galafold / Migalastat / AT1001 Sales Forecast
23.2.6. LUPKYNIS® / Voclosporin Sales Forecast
23.2.7. Sibnayal® / ADV7103 Sales Forecast
23.2.8. Tarpeyo® / Nef-301 / Nefigard-OLE / Nefecon / Kinpeygo Sales Forecast
23.2.9. TERLIVAZ® / Terlipressin Sales Forecast
23.2.10. Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast
23.2.11. ULTOMIRIS® / Ravulizumab-cwvz Sales Forecast

23.3. Phase III Rare Kidney Disease Therapies Market: Sales Forecast
23.3.1. APL-2 / Pegcetacoplan/ Aspaveli / EMPAVELI / SYFOVRE Sales Forecast
23.3.2. Atacicept / VT-001 Sales Forecast
23.3.3. Atrasentan / CHK-01 / Atrasentan Hydrochloride / ABT-627 / Xinlay Sales Forecast
23.3.4. FILSPARI® / Sparsentan / RE-021 Sales Forecast
23.3.5. IONIS-FB-LRX / RO-7434656 / ASO Factor B / ISIS-696844 / RG6299 Sales Forecast
23.3.6. Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast
23.3.7. Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast
23.3.8. Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast
23.3.9. Lucerastat / ACT 434964 / OGT 923 Sales Forecast
23.3.10. MIL62 Sales Forecast
23.3.11. Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast
23.3.12. Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast
23.3.13. Repagermanium / DMX-200 Sales Forecast
23.3.14. Sibeprenlimab / VIS-649 Sales Forecast
23.3.15. SNP-ACTH / SNP ACTH (1-39) Sales Forecast
23.3.16. Telitacicept / RC18 Sales Forecast
23.3.17. Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast
23.3.18. Venglustat / Ibiglustat / GZ402671 Sales Forecast

24. RARE KIDNEY DISEASES MARKET, BY LEADING DRUG DEVELOPERS
24.1. Chapter Overview
24.2. Rare Kidney Diseases Market: Distribution by Leading Drug Developers, 2024 (USD Million)
24.2. Rare Kidney Diseases Market: Distribution by Leading Drug Developers, 2035 (USD Million)

25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Company A
25.2.1. Company Snapshot
25.2.2. Interview Transcript: Chief Executive Officer

25.3. Chapter Overview
25.3. Company B
25.3.1. Company Snapshot
25.3.2. Interview Transcript: Associate BD Director

26 APPENDIX I: TABULATED DATA

27 APPENDIX I1: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 1.1 Research Methodology: Project Methodology
Figure 1.2 Research Methodology: Forecast Methodology
Figure 3.1 Executive Summary: Overall Market Landscape
Figure 3.2 Executive Summary: Partnerships and Collaborations
Figure 3.3 Executive Summary: Funding and Investment Analysis
Figure 3.4 Executive Summary: Clinical Trial Analysis
Figure 3.5 Executive Summary: Key Opinion Leaders
Figure 3.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 4.1 Key Historical Events
Figure 4.2 Factors Contributing to Rare Kidney Disorders
Figure 4.3 Types of Rare Kidney Diseases
Figure 4.4 Challenges Associated with RKD Diagnosis and Treatment
Figure 4.5 Selection of Therapeutic Targets for Rare Kidney Diseases
Figure 4.6 Technological Advancements in Rare Kidney Diseases Domain
Figure 5.1 Rare Kidney Diseases: Distribution by Phase of Development
Figure 5.2 Rare Kidney Diseases: Distribution by Route of Administration
Figure 5.3 Rare Kidney Diseases: Distribution by Type Molecule
Figure 5.4 Rare Kidney Diseases: Distribution by Target Disease Indication
Figure 5.5 Rare Kidney Diseases: Distribution by Type of Biologic
Figure 5.6 Rare Kidney Diseases: Distribution by Type of Therapy
Figure 5.7 Rare Kidney Diseases: Distribution by Dosing Frequency
Figure 5.8 Rare Kidney Diseases: Distribution by Target Patient Segment
Figure 5.9 Rare Kidney Diseases: Key Facts on Drug Designation
Figure 5.10 Rare Kidney Diseases Developers: Distribution by Year of Establishment
Figure 5.11 Rare Kidney Diseases Developers: Distribution by Company Size
Figure 5.12 Rare Kidney Diseases Developers: Distribution by Location of Headquarters
Figure 5.13 Most Active Players: Distribution by Number of Therapies
Figure 6.1 AstraZeneca: Annual Revenues, FY 2018- FY 2023 (USD Billion)
Figure 6.2 Chinook Therapeutics: Annual Revenues, FY 2018- Q1 FY 2023 (USD Million)
Figure 6.3 Horizon Therapeutics: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 6.4 Jiangsu Hengrui Pharmaceuticals: Annual Revenues, FY 2018-FY 2022 (CNY Million)
Figure 6.5 Novartis: Annual Revenues, FY 2018-FY 2023 (USD Billion)
Figure 6.6 Omeros: Annual Revenues, FY 2018-FY 2022 (USD Million)
Figure 6.7 Roche: Annual Revenues, FY 2018-FY 2023 (CHF Billion)
Figure 6.8 Sanofi: Annual Revenues, FY 2018-FY 2023 (EUR Billion)
Figure 6.9 Travere Therapeutics: Annual Revenue, FY 2018-9M FY 2023 (USD Million)
Figure 8.1 Company Competitiveness Analysis: Rare Kidney Disease Therapies Developers based in North America
Figure 8.2 Company Competitiveness Analysis: Rare Kidney Disease Therapies Developers based in Europe
Figure 8.3 Company Competitiveness Analysis: Rare Kidney Disease Therapies Developers based in Asia-Pacific and Rest of the World
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Target Disease Indication
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.6 Most Active Players: Distribution by Number of Partnerships
Figure 9.7 Partnerships and Collaborations: Local and International Deals
Figure 9.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 10.1 Funding and Investments: Distribution by Year of Investment, 2019-2023
Figure 10.2 Funding and Investments: Distribution by Amount Invested (USD Million)
Figure 10.3 Funding and Investments: Distribution by Type of Funding
Figure 10.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 10.5 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Figure 10.6 Funding and Investments: Distribution by Target Disease Indication
Figure 10.7 Funding and Investments: Distribution by Geography
Figure 10.8 Most Active Players: Distribution by Number of Instances
Figure 10.9 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 10.10 Leading Investors: Distribution by Number of Instances
Figure 11.1 Clinical Trial Analysis: Cumulative Year-wise Trend, 2019-2023
Figure 11.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 11.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 11.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 11.5 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Figure 11.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 11.7 Clinical Trial Analysis: Distribution by Study Design
Figure 11.8 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Figure 11.9 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 11.10 Clinical Trial Analysis: Distribution by Gender of Patients
Figure 11.11 Most Active Industry Players: Analysis by Number of Trials
Figure 11.12 Most Active Non-Industry Players: Analysis by Number of Trials
Figure 11.13 Clinical Trial Analysis: Distribution by Geography and Trial Status (Number of Trials)
Figure 11.14 Clinical Trial Analysis: Distribution by Geography and Trial Status (Patients Enrolled)
Figure 12.1 Clinical and Commercial Attractiveness Analysis
Figure 13.1 Rare Kidney Disease Therapies KOL Analysis: Distribution by Type of KOL
Figure 13.2 Rare Kidney Disease Therapies KOL Analysis: Distribution by Type of Organization
Figure 13.3 Rare Kidney Disease Therapies KOL Analysis: Distribution by Target Disease Indication
Figure 13.4 Rare Kidney Disease Therapies KOL Analysis: Distribution by Industry Affiliated Organization
Figure 13.5 Rare Kidney Disease Therapies KOL Analysis: Distribution by Non-Industry Affiliated Organization
Figure 13.6 Rare Kidney Disease Therapies KOL Analysis: Geographical Distribution of KOLs
Figure 13.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
Figure 13.8 Most Prominent KOLs: Peer Group 2 (Study Directors)
Figure 13.9 Most Prominent KOLs: Peer Group 3 (Study Chairs)
Figure 13.10 Most Prominent KOLs: Distribution by RA score
Figure 16.1 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Base Scenario (USD Billion)
Figure 16.2 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Billion)
Figure 16.3 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Billion)
Figure 17.1 Global Rare Kidney Disease Market: Distribution by Target Disease Indication, 2024, 2030 and 2035 (USD Billion)
Figure 17.2 Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome, Forecasted Estimates, till 2035 (USD Billion)
Figure 17.3 Rare Kidney Disease Market for Fabry Disease, Forecasted Estimates, till 2035 (USD Billion)
Figure 17.4 Rare Kidney Disease Market for Immunoglobulin A Nephropathy, Forecasted Estimates, till 2035 (USD Billion)
Figure 17.5 Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis, Forecasted Estimates, till 2035 (USD Billion)
Figure 17.6 Rare Kidney Disease Market for Autosomal Dominant Polycystic Kidney Disease, Forecasted Estimates, till 2035 (USD Billion)
Figure 17.7 Rare Kidney Disease Market for Lupus Nephritis, Forecasted Estimates, till 2035 (USD Billion)
Figure 17.8 Rare Kidney Disease Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Figure 18.1 Global Rare Kidney Disease Market: Distribution by Type of Molecule, 2024, 2030 and 2035 (USD Billion)
Figure 18.2 Rare Kidney Disease Market for Small Molecules, Forecasted Estimates, till 2035 (USD Billion)
Figure 18.3 Rare Kidney Disease Market for Biologics, Forecasted Estimates, till 2035 (USD Billion)
Figure 19.1 Global Rare Kidney Disease Market: Distribution by Type of Biologics, 2024, 2030 and 2035 (USD Billion)
Figure 19.2 Rare Kidney Disease Market for Monoclonal Antibodies, Forecasted Estimates, till 2035 (USD Billion)
Figure 19.3 Rare Kidney Disease Market for Proteins, Forecasted Estimates, till 2035 (USD Billion)
Figure 20.1 Global Rare Kidney Disease Market: Distribution by Route of Administration, 2024, 2030 and 2035 (USD Billion)
Figure 20.2 Rare Kidney Disease Market for Oral, Forecasted Estimates, till 2035 (USD Billion)
Figure 20.3 Rare Kidney Disease Market for Intravenous, Forecasted Estimates, till 2035 (USD Billion)
Figure 20.4 Rare Kidney Disease Market for Subcutaneous, Forecasted Estimates, till 2035 (USD Billion)
Figure 20.5 Rare Kidney Disease Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Figure 21.1 Global Rare Kidney Disease Market: Distribution by Type of Therapy, 2024, 2030 and 2035 (USD Billion)
Figure 21.2 Rare Kidney Disease Market for Monotherapy, Forecasted Estimates, till 2035 (USD Billion)
Figure 21.3 Rare Kidney Disease Market for Combination Therapy, Forecasted Estimates, till 2035 (USD Billion)
Figure 22.1 Global Rare Kidney Disease Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035 (USD Billion)
Figure 22.2 Rare Kidney Disease Market in North America, Forecasted Estimates, till 2035 (USD Billion)
Figure 22.3 Rare Kidney Disease Market in Europe, Forecasted Estimates, till 2035 (USD Billion)
Figure 22.4 Rare Kidney Disease Market in Asia-Pacific, Forecasted Estimates, till 2035 (USD Billion)
Figure 22.5 Rare Kidney Disease Market in Rest of the World, Forecasted Estimates, till 2035 (USD Billion)
Figure 23.1 Approved Rare Kidney Disease Therapies Market, Agalsidase Beta BS I.V. Infusion / Agalsidase beta / JR-051 Sales Forecast, till 2035 (USD Million)
Figure 23.2 Approved Rare Kidney Disease Therapies Market, Benlysta® / Belimumab Sales Forecast, till 2035 (USD Million)
Figure 23.3 Approved Rare Kidney Disease Therapies Market, Elfabrio® / PRX-102 / Pegunigalsidase Alfa Sales Forecast, till 2035 (USD Million)
Figure 23.4 Approved Rare Kidney Disease Therapies Market, FILSPARI® / Sparsentan / RE-021 Sales Forecast, till 2035 (USD Million)
Figure 23.5 Approved Rare Kidney Disease Therapies Market, Galafold / Migalastat / AT1001 Sales Forecast, till 2035 (USD Million)
Figure 23.6 Approved Rare Kidney Disease Therapies Market, LUPKYNIS® / Voclosporin Sales Forecast, till 2035 (USD Million)
Figure 23.7 Approved Rare Kidney Disease Therapies Market, Sibnayal® / ADV7103 Sales Forecast, till 2035 (USD Million)
Figure 23.8 Approved Rare Kidney Disease Therapies Market, Tarpeyo® / Nef-301 / Nefigard-OLE / Nefecon / Kinpeygo Sales Forecast, till 2035 (USD Million)
Figure 23.9 Approved Rare Kidney Disease Therapies Market TERLIVAZ® / Terlipressin Sales Forecast, till 2035 (USD Million)
Figure 23.10 Approved Rare Kidney Disease Therapies Market Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast, till 2035 (USD Million)
Figure 23.11 Approved Rare Kidney Disease Therapies Market ULTOMIRIS® / Ravulizumab-cwvz Sales Forecast, till 2035 (USD Million)
Figure 23.12 Phase III Rare Kidney Disease Therapies Market APL-2 / Pegcetacoplan/ Aspaveli / EMPAVELI / SYFOVRE Sales Forecast, till 2035 (USD Million)
Figure 23.13 Phase III Rare Kidney Disease Therapies Market Atacicept / VT-001 Sales Forecast, till 2035 (USD Million)
Figure 23.14 Phase III Rare Kidney Disease Therapies Market Atrasentan / CHK-01 / Atrasentan Hydrochloride / ABT-627 / Xinlay Sales Forecast, till 2035 (USD Million)
Figure 23.15 Phase III Rare Kidney Disease Therapies Market FILSPARI® / Sparsentan / RE-021 Sales Forecast, till 2035 (USD Million)
Figure 23.16 Phase III Rare Kidney Disease Therapies Market IONIS-FB-LRX / RO-7434656 / ASO Factor B / ISIS-696844 / RG62 Sales Forecast, till 2035 (USD Million)
Figure 23.17 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
Figure 23.18 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
Figure 23.19 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
Figure 23.20 Phase III Rare Kidney Disease Therapies Market Lucerastat / ACT 434964 / OGT 923 Sales Forecast, till 2035 (USD Million)
Figure 23.21 Phase III Rare Kidney Disease Therapies MIL62 Sales Forecast, till 2035 (USD Million)
Figure 23.22 Phase III Rare Kidney Disease Therapies Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast, till 2035 (USD Million)
Figure 23.23 Phase III Rare Kidney Disease Therapies Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast, till 2035 (USD Million)
Figure 23.24 Phase III Rare Kidney Disease Therapies Repagermanium / DMX-200 Sales Forecast, till 2035 (USD Million)
Figure 23.25 Phase III Rare Kidney Disease Therapies Market Sibeprenlimab / VIS-649 Sales Forecast, till 2035 (USD Million)
Figure 23.26 Phase III Rare Kidney Disease Therapies Market SNP-ACTH / SNP ACTH (1-39) Sales Forecast, till 2035 (USD Million)
Figure 23.27 Phase III Rare Kidney Disease Therapies Market Telitacicept / RC18 Sales Forecast, till 2035 (USD Million)
Figure 23.28 Phase III Rare Kidney Disease Therapies Market Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast, till 2035 (USD Million)
Figure 23.29 Phase III Rare Kidney Disease Therapies Market Venglustat / Ibiglustat / GZ402671 Sales Forecast, till 2035 (USD Million)
Figure 24.1 Rare Kidney Disease Market: Distribution by Leading Drug Developers (based on sales of rare kidney disease therapies in the year 2024 (USD Million)
Figure 24.2 Rare Kidney Disease Market: Distribution by Leading Drug Developers (based on sales of rare kidney disease therapies in the year 2035 (USD Million)

List Of Tables

Table 5.1 List of Rare Kidney Disease Therapies
Table 2.2 List of Rare Kidney Disease Therapies Developers
Table 9.1 Rare Kidney Disease Therapies: List of Partnerships and Collaborations, 2019-2023
Table 10.1 Rare Kidney Disease Therapies: List of Funding and Investments, 2019-2023
Table 11.1. Rare Kidney Disease Therapies: List of Clinical Trials, 2019-2023
Table 13.1. Rare Kidney Disease Therapies: List of Key Opinion Leaders (KOLs)
Table 16.1 Rare Kidney Disease Therapies: List of Forecasted Therapies
Table 26.1 Rare Kidney Diseases: Distribution by Phase of Development
Table 26.2 Rare Kidney Diseases: Distribution by Route of Administration
Table 26.3 Rare Kidney Diseases: Distribution by Type Molecule
Table 26.4 Rare Kidney Diseases: Distribution by Target Disease Indication
Table 26.5 Rare Kidney Diseases: Distribution by Type of Biologic
Table 26.6 Rare Kidney Diseases: Distribution by Type of Therapy
Table 26.7 Rare Kidney Diseases: Distribution by Dosing Frequency
Table 26.8 Rare Kidney Diseases: Distribution by Target Patient Segment
Table 26.9 Rare Kidney Diseases: Key Facts on Drug Designation
Table 26.10 Rare Kidney Diseases Developers: Distribution by Year of Establishment
Table 26.11 Rare Kidney Diseases Developers: Distribution by Company Size
Table 26.12 Rare Kidney Diseases Developers: Distribution by Location of Headquarters
Table 26.13 Most Active Players: Distribution by Number of Therapies
Table 26.14 AstraZeneca: Annual Revenues, FY 2018- FY 2023 (USD Billion)
Table 26.15 Chinook Therapeutics: Annual Revenues, FY 2018- Q1 FY 2023 (USD Million)
Table 26.16 Horizon Therapeutics: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 26.17 Jiangsu Hengrui Pharmaceuticals: Annual Revenues, FY 2018-FY 2022 (CNY Million)
Table 26.18 Novartis: Annual Revenues, FY 2018-FY 2023 (USD Billion)
Table 26.19 Omeros: Annual Revenues, FY 2018-FY 2022 (USD Million)
Table 26.20 Roche: Annual Revenues, FY 2018-FY 2023 (CHF Billion)
Table 20.21 Sanofi: Annual Revenues, FY 2018-FY 2023 (EUR Billion)
Table 26.22 Travere Therapeutics: Annual Revenue, FY 2018-9M FY 2023 (USD Million)
Table 26.23 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Table 26.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 26.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 26.26 Partnerships and Collaborations: Distribution by Target Disease Indication
Table 26.27 Partnerships and Collaborations: Distribution by Type of Partner
Table 26.28 Most Active Players: Distribution by Number of Partnerships
Table 26.29 Partnerships and Collaborations: Local and International Deals
Table 26.30 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 26.31 Funding and Investments: Distribution by Year of Investment, 2019-2023
Table 26.32 Funding and Investments: Distribution by Amount Invested (USD Million)
Table 26.33 Funding and Investments: Distribution by Type of Funding
Table 26.34 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Table 26.35 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Table 26.36 Funding and Investments: Distribution by Target Disease Indication
Table 26.37 Funding and Investments: Distribution by Geography
Table 26.38 Most Active Players: Distribution by Number of Instances
Table 26.39 Most Active Players: Distribution by Amount Invested (USD Million)
Table 26.40 Leading Investors: Distribution by Number of Instances
Table 26.41 Clinical Trial Analysis: Cumulative Year-wise Trend, 2019-2023
Table 26.42 Clinical Trial Analysis: Distribution by Trial Status
Table 26.43 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 26.44 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Table 26.45 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Table 26.46 Clinical Trial Analysis: Distribution by Trial Phase
Table 26.47 Clinical Trial Analysis: Distribution by Study Design
Table 26.48 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Table 26.49 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 26.50 Clinical Trial Analysis: Distribution by Gender of Patients
Table 26.51 Most Active Industry Players: Analysis by Number of Trials
Table 26.52 Most Active Non-Industry Players: Analysis by Number of Trials
Table 26.53 Clinical Trial Analysis: Distribution by Geography and Trial Status (Number of Trials)
Table 26.54 Clinical Trial Analysis: Distribution by Geography and Trial Status (Patients Enrolled)
Table 26.55 Rare Kidney Disease Therapies KOL Analysis: Distribution by Type of KOL
Table 26.56 Rare Kidney Disease Therapies KOL Analysis: Distribution by Type of Organization
Table 26.57 Rare Kidney Disease Therapies KOL Analysis: Distribution by Target Disease Indication
Table 26.58 Rare Kidney Disease Therapies KOL Analysis: Distribution by Industry Affiliated Organization
Table 26.59 Rare Kidney Disease Therapies KOL Analysis: Distribution by Non-Industry Affiliated Organization
Table 26.60 Rare Kidney Disease Therapies KOL Analysis: Geographical Distribution of KOLs
Table 26.61 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
Table 26.62 Most Prominent KOLs: Peer Group 2 (Study Directors)
Table 26.63 Most Prominent KOLs: Peer Group 3 (Study Chairs)
Table 26.64 Most Prominent KOLs: Distribution by RA score
Table 26.65 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Base Scenario (USD Billion)
Table 26.66 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Billion )
Table 26.67 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Billion )
Table 26.68 Global Rare Kidney Disease Market: Distribution by Target Disease Indication, 2024, 2030 and 2035 (USD Billion )
Table 26.69 Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome, Forecasted Estimates, till 2035 (USD Billion )
Table 26.70 Rare Kidney Disease Market for Fabry Disease, Forecasted Estimates, till 2035 (USD Billion )
Table 26.71 Rare Kidney Disease Market for Immunoglobulin A Nephropathy, Forecasted Estimates, till 2035 (USD Billion )
Table 26.72 Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis, Forecasted Estimates, till 2035 (USD Billion )
Table 26.73 Rare Kidney Disease Market for Autosomal Dominant Polycystic Kidney Disease, Forecasted Estimates, till 2035 (USD Billion )
Table 26.74 Rare Kidney Disease Market for Lupus Nephritis, Forecasted Estimates, till 2035 (USD Billion )
Table 26.75 Rare Kidney Disease Market for Others, Forecasted Estimates, till 2035 (USD Billion )
Table 26.76 Global Rare Kidney Disease Market: Distribution by Type of Molecule, 2024, 2030 and 2035 (USD Billion )
Table 26.77 Rare Kidney Disease Market for Small Molecules, Forecasted Estimates, till 2035 (USD Million)
Table 26.78 Rare Kidney Disease Market for Biologics, Forecasted Estimates, till 2035 (USD Billion)
Table 26.79 Global Rare Kidney Disease Market: Distribution by Type of Biologics, 2024, 2030 and 2035 (USD Billion)
Table 26.80 Rare Kidney Disease Market for Monoclonal Antibodies, Forecasted Estimates, till 2035 (USD Billion)
Table 26.81 Rare Kidney Disease Market for Proteins, Forecasted Estimates, till 2035 (USD Billion)
Table 26.82 Global Rare Kidney Disease Market: Distribution by Route of Administration, 2024, 2030 and 2035 (USD Billion)
Table 26.83 Rare Kidney Disease Market for Oral, Forecasted Estimates, till 2035 (USD Billion)
Table 26.84 Rare Kidney Disease Market for Intravenous, Forecasted Estimates, till 2035 (USD Billion)
Table 26.85 Rare Kidney Disease Market for Subcutaneous, Forecasted Estimates, till 2035 (USD Billion)
Table 26.86 Rare Kidney Disease Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 26.87 Global Rare Kidney Disease Market: Distribution by Type of Therapy, 2024, 2030 and 2035 (USD Billion)
Table 26.88 Rare Kidney Disease Market for Monotherapy, Forecasted Estimates, till 2035 (USD Billion)
Table 26.89 Rare Kidney Disease Market for Combination Therapy, Forecasted Estimates, till 2035 (USD Billion)
Table 26.90 Global Rare Kidney Disease Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035 (USD Billion)
Table 26.91 Rare Kidney Disease Market in North America, Forecasted Estimates, till 2035 (USD Billion)
Table 26.92 Rare Kidney Disease Market in Europe, Forecasted Estimates, till 2035 (USD Billion)
Table 26.93 Rare Kidney Disease Market in Asia-Pacific, Forecasted Estimates, till 2035 (USD Billion)
Table 26.94 Rare Kidney Disease Market in Rest of the World, Forecasted Estimates, till 2035 (USD Billion)
Table 27.95 Approved Rare Kidney Disease Therapies Market, Agalsidase Beta BS I.V. Infusion / Agalsidase beta / JR-051 Sales Forecast, till 2035 (USD Million)
Table 27.96 Approved Rare Kidney Disease Therapies Market, Benlysta® / Belimumab Sales Forecast, till 2035 (USD Million)
Table 27.97 Approved Rare Kidney Disease Therapies Market, Elfabrio® / PRX-102 / Pegunigalsidase Alfa Sales Forecast, till 2035 (USD Million)
Table 27.98 Approved Rare Kidney Disease Therapies Market, FILSPARI® / Sparsentan / RE-021 Sales Forecast, till 2035 (USD Million)
Table 27.99 Approved Rare Kidney Disease Therapies Market, Galafold / Migalastat / AT1001 Sales Forecast, till 2035 (USD Million)
Table 27.100 Approved Rare Kidney Disease Therapies Market, LUPKYNIS® / Voclosporin Sales Forecast, till 2035 (USD Million)
Table 27.101 Approved Rare Kidney Disease Therapies Market, Sibnayal® / ADV7103 Sales Forecast, till 2035 (USD Million)
Table 27.102 Approved Rare Kidney Disease Therapies Market, Tarpeyo® / Nef-301 / Nefigard-OLE / Nefecon / Kinpeygo Sales Forecast, till 2035 (USD Million)
Table 27.103 Approved Rare Kidney Disease Therapies Market TERLIVAZ® / Terlipressin Sales Forecast, till 2035 (USD Million)
Table 27.104 Approved Rare Kidney Disease Therapies Market Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast, till 2035 (USD Million)
Table 27.105 Approved Rare Kidney Disease Therapies Market ULTOMIRIS® / Ravulizumab-cwvz Sales Forecast, till 2035 (USD Million)
Table 27.106 Phase III Rare Kidney Disease Therapies Market APL-2 / Pegcetacoplan/ Aspaveli / EMPAVELI / SYFOVRE Sales Forecast, till 2035 (USD Million)
Table 27.107 Phase III Rare Kidney Disease Therapies Market Atacicept / VT-001 Sales Forecast, till 2035 (USD Million)
Table 27.108 Phase III Rare Kidney Disease Therapies Market Atrasentan / CHK-01 / Atrasentan Hydrochloride / ABT-627 / Xinlay Sales Forecast, till 2035 (USD Million)
Table 27.109 Phase III Rare Kidney Disease Therapies Market FILSPARI® / Sparsentan / RE-021 Sales Forecast, till 2035 (USD Million)
Table 27.110 Phase III Rare Kidney Disease Therapies Market IONIS-FB-LRX / RO-7434656 / ASO Factor B / ISIS-696844 / RG62 Sales Forecast, till 2035 (USD Million)
Table 27.111 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
Table 27.112 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
Table 27.113 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
Table 27.114 Phase III Rare Kidney Disease Therapies Market Lucerastat / ACT 434964 / OGT 923 Sales Forecast, till 2035 (USD Million)
Table 27.115 Phase III Rare Kidney Disease Therapies MIL62 Sales Forecast, till 2035 (USD Million)
Table 27.116 Phase III Rare Kidney Disease Therapies Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast, till 2035 (USD Million)
Table 27.117 Phase III Rare Kidney Disease Therapies Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast, till 2035 (USD Million)
Table 27.118 Phase III Rare Kidney Disease Therapies Repagermanium / DMX-200 Sales Forecast, till 2035 (USD Million)
Table 27.119 Phase III Rare Kidney Disease Therapies Market Sibeprenlimab / VIS-649 Sales Forecast, till 2035 (USD Million)
Table 27.120 Phase III Rare Kidney Disease Therapies Market SNP-ACTH / SNP ACTH (1-39) Sales Forecast, till 2035 (USD Million)
Table 27.121 Phase III Rare Kidney Disease Therapies Market Telitacicept / RC18 Sales Forecast, till 2035 (USD Million)
Table 27.122 Phase III Rare Kidney Disease Therapies Market Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast, till 2035 (USD Million)
Table 27.123 Phase III Rare Kidney Disease Therapies Market Venglustat / Ibiglustat / GZ402671 Sales Forecast, till 2035 (USD Million)
Table 27.124 Global Rare Kidney Disease Market: Distribution by Leading Drug Developers (based on sales of rare kidney disease therapies in the year 2024 (USD Million))
Table 27.125 Global Rare Kidney Disease Market: Distribution by Leading Drug Developers (based on sales of rare kidney disease therapies in the year 2035 (USD Million))

List Of Companies And Organizations

  1. 4D Molecular Therapeutics
  2. 5AM Ventures
  3. AbbVie
  4. AceLink Therapeutics
  5. ACELYRIN
  6. Achillion Pharmaceuticals
  7. Aduro Biotech
  8. ADVANZ PHARMA
  9. Advicenne
  10. Aevitas Therapeutics (A subsidiary of Fortress Biotech)
  11. Affimed
  12. Ain Shams University
  13. Aldeyra Therapeutics
  14. Alexion Pharmaceuticals (A subsidiary of AstraZeneca)
  15. Algomedix
  16. Alpine Immune Sciences
  17. Amgen
  18. Amicus Therapeutics
  19. Amyndas Pharmaceuticals 
  20. Anelixis Therapeutics
  21. Annexon Biosciences
  22. Apellis Pharmaceuticals
  23. APIE Therapeutics
  24. argenx
  25. Arrowhead Pharmaceuticals
  26. Artiva Biotherapeutics
  27. ARYA Sciences Acquisition Corp IV
  28. Asahi Kasei
  29. Assistance Publique - Hôpitaux de Paris
  30. Astellas Pharma
  31. AstraZeneca
  32. Aurinia Pharmaceuticals
  33. Avanzanite Bioscience
  34. Bayer
  35. Beam Therapeutics
  36. BeiGene
  37. BioCity
  38. Biocon
  39. Biogen
  40. Biohaven
  41. Birch Therapeutics
  42. Boehringer Ingelheim
  43. BridgeBio
  44. Bristol-Myers Squibb
  45. Cabaletta Bio
  46. Calliditas Therapeutics
  47. CANbridge Life Sciences
  48. CareDx
  49. Cellares 
  50. CENTOGENE
  51. Cerium Pharmaceuticals
  52. Certa Therapeutics
  53. ChemoCentryx (Acquired by Amgen)
  54. Chiesi Farmaceutici
  55. Children's Hospital of Chongqing Medical University
  56. Chinook Therapeutics
  57. Chugai Pharmaceutical
  58. Codexis 
  59. CSL
  60. Delta4
  61. Dimerix 
  62. EcoR1 Capital
  63. Lundbeck 
  64. Eledon Pharmaceuticals
  65. Eleva
  66. ElevateBio
  67. Eloxx Pharmaceuticals
  68. ENYO Pharma
  69. Equillium
  70. Everest Medicines
  71. Evotec
  72. ExCEEd Orphan
  73. Exeltis
  74. Foresee Pharmaceuticals
  75. FrostPharma
  76. GC Cell
  77. GENERIUM
  78. Genpharm
  79. Gilead Sciences
  80. Ginkgo Bioworks
  81. Goldfinch Bio
  82. GSK
  83. Guangdong Academy of Medical Sciences
  84. Hanmi Pharmaceutical
  85. Hansoh Pharma
  86. Healx 
  87. HI-Bio
  88. Horizon Therapeutics
  89. IASO Biotherapeutics
  90. Idorsia Pharmaceuticals
  91. IgA Nephropathy Foundation
  92. IGAN Biosciences
  93. ImmPACT Bio
  94. InflamaCORE 
  95. Inmunova
  96. Ionis Pharmaceuticals
  97. Janus Henderson Investors
  98. JCR Pharma
  99. Jiangsu Hengrui Pharmaceuticals
  100. Johns Hopkins University School of Medicine
  101. Just – Evotec Biologics
  102. Keymed Biosciences
  103. Kezar Life Sciences
  104. Kira Pharmaceuticals
  105. Komodo Health
  106. Kyverna Therapeutics
  107. LogicBio Therapeutics
  108. Lonza
  109. M6P Therapeutics
  110. MAB Works
  111. Mallinckrodt Pharmaceuticals
  112. Mayo Clinic
  113. Medison Pharma
  114. Medpace
  115. Merck
  116. Morehouse School of Medicine
  117. MorphoSys
  118. myTomorrows
  119. Nacuity Pharmaceuticals
  120. NephCure
  121. Novartis
  122. NovelMed 
  123. Novo Nordisk
  124. Novotech
  125. OccuRx
  126. Ocelot Bio
  127. Octagon Capital
  128. Omeros
  129. Ono Pharmaceutical
  130. Oraxion Therapeutics (A subsidiary of Aten Porus Lifesciences)
  131. OrbiMed
  132. Orphan
  133. Otsuka Pharmaceutical
  134. Oxford BioMedica
  135. Papillon Therapeutics 
  136. Peking Union Medical College Hospital
  137. Pfizer
  138. Polycystic Kidney Disease Charity 
  139. Poxel
  140. Protalix Biotherapeutics
  141. RA Capital Management
  142. Recordati Rare Diseases
  143. Regulus Therapeutics
  144. Reistone Biopharma
  145. RemeGen Biosciences
  146. Renocell Biotechnology
  147. River 3 Renal 
  148. Roche
  149. Rock Springs Capital
  150. Rohto Pharmaceutical 
  151. Rona Therapeutics
  152. RTW Investments
  153. Sangamo Therapeutics
  154. Sanofi
  155. SCOHIA PHARMA
  156. Selecta Biosciences
  157. Shanghai Jiaolian Drug Development
  158. Shanghai Pharmaceuticals Holding
  159. Silence Therapeutics
  160. SPA - Antibiotic Products Company
  161. Sphera Biotech
  162. Sumitomo Dainippon Pharma
  163. Suncadia Medicine
  164. Surveyor Capital
  165. Swedish Orphan Biovitrum AB
  166. SynAct Pharma
  167. Synlogic
  168. Taiba Healthcare
  169. Takeda
  170. Children's Hospital of Zhejiang University School of Medicine
  171. The National Institutes of Health
  172. Tigermed
  173. Travere Therapeutics 
  174. Truveta
  175. TwinPharma
  176. UMass Medical School
  177. uniQure
  178. University of Pennsylvania
  179. Vera Therapeutics
  180. Verily
  181. Vertex Pharmaceuticals
  182. Viatris
  183. Vida Ventures
  184. Visterra (a subsidiary of Otsuka Pharmaceutical)
  185. Westlake Village BioPartners
  186. WuXi Advanced Therapies
  187. WuXi Biologics
  188. XORTX Therapeutics
  189. Zai Lab
  190. ZyVersa Therapeutics

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com